Department of Basic Sciences, Faculty of Dentistry, University of Kufa, Kufa, Iraq.
Middle Euphrates Unit for Cancer Research, Faculty of Medicine, University of Kufa, Kufa, Iraq.
J Med Life. 2022 Apr;15(4):520-525. doi: 10.25122/jml-2021-0415.
Differentiated thyroid tumors (DTC) are the most common indolent tumors associated with a good prognosis compared with other tumors. Its incidence during the last few decades has increased. DTC includes papillary carcinoma and follicular carcinoma. The BRAF is the most prevalent genetic mutation in thyroid carcinoma, occurring in more than 50% of papillary thyroid cancers (PTCs). The study aimed to evaluate BRAF expression in differentiated thyroid tumors with papillary-like nuclear features. Formalin-fixed paraffin-embedded blocks (FFPE) were collected from archival samples of patients in private histopathology labs in Al-Najaf city from 55 cases, which included 27 papillary thyroid carcinoma (PTC) cases, 10 cases of NIFTP, 13 FVPTC cases, 2 papillary microcarcinoma cases, and 3 NIFTP coexist with papillary microcarcinoma cases. All samples were stained using the immunohistochemistry method in the Middle Euphrates unit for cancer research at the University of Kufa/Faculty of Medicine. 15/55 (27.3%) of cases increased BRAF expression. The BRAF expression was statistically significant with tumor type (p=0.008). The higher expression was associated with 13 (48.15%) of PTC cases. However, the BRAF expression did not correlate with gender (p=0.2), tumor size (p=0.07), and tumor focality (p=0.09). BRAF V600E has prognostic value as it correlates with tumor progression.
分化型甲状腺肿瘤（DTC）是最常见的惰性肿瘤，与其他肿瘤相比，预后良好。在过去几十年中，其发病率有所增加。DTC 包括乳头状癌和滤泡状癌。BRAF 是甲状腺癌中最常见的基因突变，发生在超过 50%的甲状腺乳头状癌（PTC）中。本研究旨在评估具有乳头状核特征的分化型甲状腺肿瘤中 BRAF 的表达。从私营组织病理学实验室存档样本中收集福尔马林固定石蜡包埋（FFPE）块，来自 55 例患者，其中包括 27 例甲状腺乳头状癌（PTC）病例、10 例非典型滤泡性肿瘤（NIFTP）、13 例滤泡状癌（FVPTC）、2 例乳头状微小癌和 3 例 NIFTP 与乳头状微小癌共存。所有样本均使用免疫组织化学方法在库法大学/医学系中幼发拉底癌症研究中部单位进行染色。55 例中有 15 例（27.3%）的 BRAF 表达增加。BRAF 的表达与肿瘤类型有统计学意义（p=0.008）。更高的表达与 13 例（48.15%）PTC 病例相关。然而，BRAF 表达与性别（p=0.2）、肿瘤大小（p=0.07）和肿瘤灶性（p=0.09）无关。BRAF V600E 具有预后价值，因为它与肿瘤进展相关。
